Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP
Status:
Completed
Trial end date:
2003-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine if the safety and tolerability of Immune Globulin
Intravenous (Human), 10% Caprylate/Chromatograph Purified (IGIV-C) is similar when infused at
two different infusion rates.
Phase:
Phase 2
Details
Lead Sponsor:
Grifols Therapeutics Inc. Grifols Therapeutics LLC
Treatments:
Antibodies gamma-Globulins Immunoglobulin G Immunoglobulins Immunoglobulins, Intravenous Rho(D) Immune Globulin